License and Collaboration Agreements - Narratives (Details) $ / shares in Units, shares in Millions		1 Months Ended		3 Months Ended	6 Months Ended	12 Months Ended
	Dec. 27, 2011 $ / shares shares	Jan. 31, 2015 USD ($) item	Jan. 31, 2012 USD ($)	Dec. 31, 2015 USD ($) $ / shares	Dec. 31, 2015 USD ($) $ / shares	Jun. 30, 2015 USD ($) $ / shares
Guarantor Obligations [Line Items]
License fee and other revenues				$ 25,403	$ 36,228
Duration of warrant issued	5 years
Number of shares under five year warrant | shares	1
Shares to be purchased under warrant, par value | $ / shares	$ 0.01			$ 0.01	$ 0.01	$ 0.01
Shares to be purchased under warrant, exercise price | $ / shares	$ 8.00
Non-refundable cash payment received			$ 30,000,000
The Bayer Group (formerly Algeta ASA) [Member]
Guarantor Obligations [Line Items]
Collaboration agreement date					2013
Upfront cash payment and other payments received under collaboration agreement					$ 6,000,000
License fee and other revenues		$ 300,000				$ 1,000,000
Number of payments receivable per contract | item		2
License costs payment period		2 years
UCB Agreement [Member]
Guarantor Obligations [Line Items]
License agreement date					May 09, 2006
Amendment agreement date					Dec. 27, 2011
Product royalties term, description					The Company is also entitled to product royalties ranging from a mid-teen to mid-twenty percentage of aggregate annual net sales under the UCB Agreement and Amendment Agreement during the product royalty term, (subject to reduction in certain circumstances).
Clinical trial study, description					On July 28, 2015, UCB announced that the two Phase 3 EMBODY(TM) clinical trials for epratuzumab in SLE did not meet the primary clinical efficacy endpoints in either dose in both studies. UCB is in the process of analyzing the full set of data from both studies.
Agreement expiration period					30 days
Termination period					60 days
Additional amounts payable after effective date of termination					$ 0
UCB Agreement [Member] | Maximum [Member]
Guarantor Obligations [Line Items]
Cash payment receivable					130,000,000
Equity investments receivable					20,000,000
Achievement of specified product sales milestones					$ 260,000,000